Health Canada approves Onureg (azacitidine tablets), first maintenance therapy for patients in remission from acute myeloid leukaemia


12 January 2021 - Onureg has shown clinically meaningful increase in overall survival for patients.

Bristol Myers Squibb Canada announced today that Health Canada has approved Onureg (azacitidine tablets) for use as the first and only maintenance therapy for adult patients with acute myeloid leukaemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment, and who are not eligible for haematopoietic stem cell transplantation.

Health Canada's approval of Onureg is based upon findings from the QUAZAR AML-001 clinical trial.

Read BMS press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada